Abstract
The paper by Sharp et al in this issue of Transfusion reports the transmission of human parvovirus 4 (PARV4) by “virus-inactivated” plasma pool-derived clotting factors, demonstrating that infection by non lipid-membrane viruses continues to be a concern for hemophiliacs and other recipients of such products 1. While the inactivation of lipid enveloped viruses such as HIV and HCV by solvent/detergent and/or heating now used in the manufacture of plasma derivatives is highly effective, such treatments (at least as performed before 1992) were not sufficient to prevent the transmission of PARV4 1. Recipients of non-pooled (from a single or few donors), non-inactivated, blood products such as plasma or platelets, while at lower risk of receiving a PARV4 containing transfusion, must also be exposed to this recently characterized virus.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
